Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Popularity (sales)

Display 15 Products per page

Gocovri
Read More
Gocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease.
June 21, 2018
Find out more
Raxatrigine
Read More
Raxatrigine (Biogen) is a peripherally and centrally acting agent that inhibits sodium channels in a state-dependent fashion. Raxatrigine shows selectivity for the Nav1.7 subtype over the other subtypes.
May 31, 2018
Find out more
Nucynta
Read More
Nucynta (tapentadol; Collegium Pharmaceutical) first gained US Food and Drug Administration (FDA) approval in November 2008 as an immediate-release formulation, for the relief of acute pain, and was the first novel opioid to be launched for pain in more than 25 years.
May 31, 2018
Find out more
Mirogabalin
Read More
Mirogabalin (Daiichi Sankyo) is an oral therapy that preferentially and selectively binds to the α2δ-1 (alpha-2 delta-1) subunit of calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.
May 31, 2018
Find out more
Lidoderm
Read More
Lidoderm is a medicated plaster containing 5% lidocaine, and was developed by Endo Pharmaceuticals. Lidocaine is an amide-type local anesthetic agent that acts by stabilizing neuronal membranes.
May 31, 2018
Find out more
Gralise
Read More
Gralise (gabapentin; Depomed) is an extended-release formulation of gabapentin, an analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), and is used for treatment of restless leg syndrome and post-herpetic neuralgia (PHN).
May 31, 2018
Find out more
Donaperminogene Seltoplasmid
Read More
Donaperminogene seltoplasmid (ViroMed), also referred to as VM202, is a DNA-based drug that is designed to produce two isoforms of HGF (hepatocyte growth factor), HGF728 and HGF723. When VM202 is delivered to the affected area by a single intramuscular injection, the drug enters a small portion of the surrounding muscle cells.
May 31, 2018
Find out more
Cebranopadol
Read More
Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a novel, first-in-class potent analgesic that has a dual mechanism of action as a potent agonist of both the nociceptin/orphanin FQ peptide receptor (NOP) and opioid peptide receptor.
May 31, 2018
Find out more
IMO-2125
Read More
IMO-2125 is a synthetic phosphorothioate oligonucleotide-based agonist of toll-like receptor 9 (TLR9) designed to mimic the bacterial DNA that normally activates TLR9.
May 23, 2018
Find out more
Seviprotimut-L
Read More
Seviprotimut-L (Polynoma/CK Life Sciences) is a polyvalent, shed-antigen vaccine in development for the adjuvant treatment of Stage IIb–III melanoma patients. Seviprotimut-L contains a combination of antigens from three proprietary melanoma cell lines, and is intended to stimulate the body’s immune system to fight cancer.
May 23, 2018
Find out more
PDR001
Read More
PDR001 (Novartis) is a fully humanized monoclonal antibody designed to inhibit the negative immunoregulatory receptor programmed death-1 (PD-1). PDR001 blocks the interaction between PD-1 and its ligands, programmed death-ligand 1 (PD-L1) and PD-L2; the signaling elicited by this interaction inhibits T-cell activation.
May 23, 2018
Find out more
Daromun
Read More
Daromun (Philogen) is a combination of Darleukin, a human vascular targeting monoclonal antibody (L19) fused to interleukin-2 (IL-2), and Fibromun, the L19 antibody linked to tumor necrosis factor (TNF). Both IL-2 and TNF are cytokines, key signaling molecules that are involved with the coordination of immunity.
May 23, 2018
Find out more
Rebinyn
Read More
Rebinyn is a glycoPEGylated rebombinant factor IX (rfIX) therapy developed by Novo Nordisk for the treatment of hemophilia B.
May 20, 2018
Find out more
Hemlibra
Read More
Hemlibra is an anti-factor IXa/X bispecific antibody, developed by Roche as a new treatment option for hemophilia A patients.
May 20, 2018
Find out more
Valoctocogene Roxaparvovec
Read More
Valoctocogene roxaparvovec (BioMarin), also known as valrox, is an adeno-associated virus-mediated gene therapy that delivers human B domain-deleted coagulation factor VIII (fVIII) to patients with hemophilia A.
May 20, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *